Skip to main content

Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared with that of Insulin Glargine in Patients with Type 1 Diabetes Mellitus

Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared with that of Insulin Glargine in Patients with Type 1 Diabetes Mellitus

Principal Investigator

Sponsor

Eli Lilly

This study is being done to find out more about LY2605541, which is an investigational drug being developed for the treatment of diabetes mellitus. This drug has not yet been approved by the Food and Drug Administration (FDA). LY2605541 is an investigational type of insulin, a hormone produced by the body to lower the levels of sugar in the blood. In this study, LY2605541 will be compared to the insulin Glargine. Insulin Glargine is a long acting form of insulin that has been approved by the FDA to be given by injection subcutaneously (under the skin). The study will look at what kind of effect LY2605541 and Glargine has on respiratory quotient (RQ), a measure of how much carbon dioxide is produced by your body compared to the amount of oxygen you breathe in) during sleep and on insulin levels in patients with type 1 diabetes. RQ gives an indication of whether your body is using fats or sugars for fuel. It is known that high insulin levels makes the body prefer use of glucose at the expense of fat, and also that using insulin for treatment of diabetes (type 2) is associated with weight gain. The purpose of this study is to see what effect this investigational drug has on the body, and whether it causes a change to how your body uses fats and sugars as fuel sources.